MoonLake Immunotherapeutics
MLTX · XNASCIK 1821586fmd_07XYEM0FVYCB22R8V0A9BPYCDMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Research and development | – | 42 | 32 | 113 | 203 |
| Total operating expenses | – | 65 | 54 | 143 | 245 |
| Operating income | (5) | (65) | (54) | (143) | (245) |
| Interest expense | – | – | 0 | 0 | 7 |
| Interest and investment income | 0 | – | – | – | – |
| Other non-operating income (expense) | 0 | 1 | – | – | – |
| Income before taxes | – | (64) | (44) | (121) | (230) |
| Income tax expense | – | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | (65) | (44) | (121) | (230) |
| Net income | (5) | (50) | (36) | (119) | (227) |